» Articles » PMID: 318493

Hydrallazine with Beta-blocker and Diuretic in the Treatment of Hypertension. A Double-blind Crossover Study

Overview
Journal Med J Aust
Specialty General Medicine
Date 1979 Oct 20
PMID 318493
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Thirty-seven hypertensive patients were treated with cyclopenthiazide, oxprenolol and hydrallazine. Blood pressure was controlled in 31 patients and a subsequent double-blind crossover study in 27 patients comparing hydrallazine with placebo confirmed the efficacy of hydrallazine in combination with diuretic and beta-adrenergic-blocking agent. The combination was effective in patients with renal hypertension and renal impairment. No adverse effects on renal function were observed. Patients who were slow acetylators had significantly better blood pressure control and more side effects. In view of the frequency of hydrallazine related side effects, prior institution of beta-adrenergic blocking drugs is desirable.

Citing Articles

Pharmacogenomics Informs Cardiovascular Pharmacotherapy.

Babayeva M, Azzi B, Loewy Z Methods Mol Biol. 2022; 2547:201-240.

PMID: 36068466 DOI: 10.1007/978-1-0716-2573-6_9.


Genotype-Guided Hydralazine Therapy.

Collins K, Raviele A, Elchynski A, Woodcock A, Zhao Y, Cooper-DeHoff R Am J Nephrol. 2020; 51(10):764-776.

PMID: 32927458 PMC: 7606720. DOI: 10.1159/000510433.


The hypotensive response to hydralazine, in triple therapy, is not related to acetylator phenotype.

Vandenburg M, Wright P, Holmes J, Rogers H, Ahmad R Br J Clin Pharmacol. 1982; 13(5):747-50.

PMID: 7082547 PMC: 1402085. DOI: 10.1111/j.1365-2125.1982.tb01452.x.


Fixed combination drug therapy.

Shenfield G Drugs. 1982; 23(6):462-80.

PMID: 7049658 DOI: 10.2165/00003495-198223060-00003.


Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?.

Ramsay L, Silas J, Ollerenshaw J, Tucker G, Phillips F, Freestone S Eur J Clin Pharmacol. 1984; 26(1):39-42.

PMID: 6714290 DOI: 10.1007/BF00546706.